Omeros (OMER) stock rocketed to a five-year high Thursday on blowout second-quarter results for its new treatment for transplant complications. The biotech company won approval for Yartemlea in December. It's the only treatment approved for patients with thrombotic microangiopathy due to a stem cell transplant.
In this condition, small blood clots form in blood vessels throughout the body.
Extract — continue reading at the source.
Similar stories
2 outlets
See how this story developed, hour by hour
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More
finance.yahoo.com
14.08.2026
Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High
investors.com
14.08.2026
Related stories
Here’s the case for Nvidia’s stock to climb 55% from here, according to BofA
Neocloud Stocks Plummet on Rising Overspend Fears. CoreWeave Down 7%, Nebius Down 5%, Terawulf Down 6%
Soon you can buy Medicare Advantage plans at Costco. What you need to know.
Eltek Ltd. Q2 2026 Earnings Call Summary
WSJ Report Sends Memory Stocks Down. SanDisk Down 9%, Micron Down 7%, Western Digital Down 5%
Microsoft is Consolidating and Will Be More Expensive Soon, So I Keep Buying